Pinnbrook Capital Management LP Makes New $18.81 Million Investment in Natera, Inc. $NTRA

Pinnbrook Capital Management LP bought a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 69,300 shares of the medical research company’s stock, valued at approximately $18,811,000. Natera makes up approximately 2.0% of Pinnbrook Capital Management LP’s portfolio, making the stock its 11th largest position.

Several other institutional investors have also recently added to or reduced their stakes in NTRA. BlackRock Inc. acquired a new position in Natera in the second quarter valued at approximately $2,962,770,000. Coatue Management LLC raised its holdings in Natera by 1,446.1% during the fourth quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after purchasing an additional 2,463,008 shares in the last quarter. Wellington Management Group LLP raised its holdings in Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after purchasing an additional 2,420,263 shares in the last quarter. Norges Bank purchased a new stake in shares of Natera during the 4th quarter worth approximately $372,398,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Natera by 10.5% during the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after buying an additional 1,225,420 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Guggenheim increased their target price on shares of Natera from $290.00 to $360.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Leerink Partners set a $330.00 price target on shares of Natera in a research report on Friday, August 7th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Stephens raised their price objective on Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, Royal Bank Of Canada lifted their target price on Natera from $275.00 to $350.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $319.38.

Natera Stock Up 2.2%

NASDAQ NTRA opened at $332.03 on Friday. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $333.56. The business’s 50-day moving average price is $274.24 and its 200 day moving average price is $229.39. The firm has a market cap of $47.86 billion, a P/E ratio of -244.14 and a beta of 1.51.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same period last year, the firm earned ($0.74) EPS. The firm’s revenue for the quarter was up 37.7% on a year-over-year basis. As a group, analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 3,076 shares of Natera stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $266.39, for a total value of $819,415.64. Following the transaction, the chief executive officer directly owned 99,897 shares in the company, valued at $26,611,561.83. This trade represents a 2.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 295 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05. Following the completion of the transaction, the insider directly owned 183,774 shares in the company, valued at $49,249,594.26. This represents a 0.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 181,045 shares of company stock valued at $41,330,968 in the last ninety days. Company insiders own 5.05% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.